LivaNova PLC filings document the regulatory disclosures of an England and Wales public limited company with ordinary shares listed on Nasdaq under LIVN. Its Form 8-K reports primarily cover operating and financial results, earnings releases, business update calls, material events, and governance changes involving senior officers.
Proxy materials describe annual general meeting procedures, shareholder voting matters, director and governance proposals, and the company’s ordinary share structure. The filings also provide formal records for capital-structure disclosures and corporate governance matters relevant to LivaNova’s medical technology operations in neurological and cardiac conditions.
LivaNova PLC (symbol: LIVN) is the issuer of record for a Form 4 filing submitted to the SEC. Liddy Anne M. reported acquisition or exercise transactions in this Form 4 filing.
LivaNova PLC (LIVN) reported that Chief Legal Officer Anne M. Liddy received a grant of 6,291 Restricted Stock Units (RSUs) on September 15, 2026 under the Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan. The RSUs vest 20% on March 30, 2027 (pro‑rated from the grant date), 40% on March 30, 2028, and 40% on March 30, 2029, and are subject to forfeiture before vesting. Each RSU represents a contingent right to receive one ordinary share of LivaNova PLC.
LivaNova PLC (LIVN) director Francesco Bianchi reported selling 3,500 Ordinary Shares on September 10, 2026 in an open-market transaction at a weighted-average price of $78.0092 per share, with individual sale prices ranging from $77.97 to $78.04. After this sale, he directly holds 4,434 Ordinary Shares, and no Rule 10b5-1 trading plan is reported for this transaction.
LivaNova PLC (LIVN) received a notice that officer Francesco Bianchi intends to sell up to 3,500 shares of Common Stock under Rule 144. The shares relate to a vesting of a restricted stock unit award on June 15, 2026, granted as part of the issuer’s equity compensation plan.
The planned sale is to be executed through Merrill Lynch, with an aggregate market value noted as $273,032.19 and 55,093,507 shares shown in the same line as contextual share data. The filing also lists Bianchi’s prior Common Stock sales during the past three months.
LivaNova PLC (LIVN) director Story Brooke reported selling 2,300 Ordinary Shares of the company on September 4, 2026 in a sale described as occurring in the open market or a private transaction at an average price of $81.42 per share. After this transaction, Brooke directly holds 7,488 Ordinary Shares, and no Rule 10b5-1 trading plan is reported.
LivaNova PLC (LIVN) received a notice that officer Brooke Story plans to sell 2,300 Ordinary Shares of LivaNova under Rule 144 through Merrill Lynch on NASDAQ. The shares have a stated aggregate market value of $187,270.14, and the filing lists 55,093,507 Ordinary Shares outstanding for this class.
The notice also explains that the shares relate to restricted stock unit awards vesting in two tranches of 1,130 shares on September 15, 2023 and 1,170 shares on June 15, 2024, granted as part of LivaNova’s equity compensation plan.
LivaNova PLC (LIVN) is the issuer of common stock covered by a notice filed for a proposed resale under Rule 144 by Franco Poletti, an officer of the company. The notice covers 10,755 shares of common stock, with an aggregate market value of $882,888.36, to be sold through Merrill Lynch on or after September 2, 2026 on NASDAQ. The shares were originally acquired through vesting of restricted stock unit awards granted as part of LivaNova’s equity compensation plan over multiple grant and vesting dates from 2015 through 2026.
LivaNova PLC (LIVN) director Francesco Bianchi reported selling 1,650 Ordinary Shares on August 31, 2026 in a sale classified as an open market or private transaction at $79.72 per share. After this transaction, he directly owns 7,934 Ordinary Shares, and no Rule 10b5-1 trading plan is reported.
LivaNova PLC (LIVN) reports that Anne M. Liddy, serving as Chief Legal Officer, has filed an initial Form 3 as a reporting insider. The filing lists no specific equity holdings or transactions at this time and includes a Power of Attorney as an exhibit.
LivaNova PLC (LIVN) received a notice that officer Francesco Bianchi plans to sell common stock under Rule 144. The notice covers 1,650 shares of LivaNova common stock to be sold through Merrill Lynch with an indicated aggregate market value of $131,538.00 as of the filing. The filing notes these shares relate to vested restricted stock unit awards from June 15, 2024 (1,387 shares) and June 15, 2023 (263 shares), granted under the issuer’s equity compensation plan. It also lists prior sales in the last three months of 1,800 shares for $136,350.00 on May 26, 2026 and 1,200 shares for $96,228.00 on June 15, 2026.
LivaNova PLC Chief Innovation Officer Ahmet Tezel exercised 12,692 Stock Appreciation Rights at a base price of $52.68 per share, receiving the same number of ordinary shares. In connection with this, 8,589 shares were withheld to pay the SARs base price, 1,428 shares were withheld to satisfy tax liability, and 2,675 shares were sold in open-market transactions at a weighted-average price of $77.7355, within a range of $77.6684–$77.7900. The SARs were granted on June 15, 2024, vest over four years from June 15, 2025, and expire on June 15, 2034.